Publications and Presentations

This page includes scientific papers published as a result of this project, conference presentations about the project and general Information on the project, e.g. project presentation, brochures, posters and relevant papers by partners.

Scientific Papers

 

  • Colm E Nestor, Raffaele Ottaviano, Diana Reinhardt, Hazel A Cruickshanks, Heidi K Mjoseng, Rhoanne C McPherson, Antonio Lentini, John P Thomson, Donncha S Dunican, Sari Pennings, Stephen M Anderton, Mikael Bensonand Richard R Meehan (2015) Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems. Genome Biology 2015, 16:11  doi:10.1186/s13059-014-0576-y
  • Kossler.N, Matheis.K.A, Ostenfeldt.N, Bach Toft.D, Dhalluin.S, Deschl.U, Kalkuhl.A. (2014) Identification of specific mRNA signatures as fingerprints for carcinogenesis in mice induced by genotoxic and non-genotoxic hepatocarcinogens. Toxicological Sciences, doi: 10.1093/toxsci/kfu248
  • Romer.M, Backert.L, Eichner.J, Zell.A. (2014) ToxDBScan: Large-Scale Similarity Screening of Toxicological Databases for Drug Candidates. International Journal of Molecular Sciences 15, 19037-19055
  • Gerbal-Chaloin.S, Dume.A-S, Briolotti.P, Klieber.S, Raulet.E, Duret.C, Fabre.J-M, Ramos.J, Maurel.P, Daujat-Chavanieu.M (2014) The WNT/ β-catenin Pathway is a Transcriptional Regulator of CYP2E1, CYP1A2 and Aryl Hydrocarbon Receptor Gene Expression in Primary Human Hepatocytes. Molecular Pharmacology (advanced published 16-09-14).
  • Eichner.J, Heubach.Y, Ruff.M, Kohlhof.H, Strobl.S, Mayer.B, Pawlak.M, templin.M.F, Zell.A (2014) RPPApipe: A pipeline for the analysis of reverse-phase protein array data. BioSystems 122, 19-24
  • Braeuning.A, Gavrilov.A, Brown.S, Wolf.R, Henderson.C.J, Schwarz.M (2014) Phenobarbital-Mediated Tumor Promotion in transgenic Mice with Humanized CAR and PXR. Toxicological Sciences 140(2):259-70
  • Romer.M, Eichner.J, Metzger.U, Templin.M.F, Plummer.S, Ellinger-Ziegelbauer.H, Zell.A (2014) Cross-Platform Toxicogenomics for the Prediction of Non-Genotoxic Hepatocarcinogenesis in Rat. PLoS ONE 9(5):e97640
  • Eichner.J, Wrzodek.C, Romer.M, Ellinger-Ziegelbauer.H, Zell.A (2014) Evaluation of Toxicogenomics Approaches for Assessing the Risk of Nongenotoxic Carcinogenicity in Rat Liver. PLoS ONE 9(5):e97678
  • Eichner.J, Rosenbaum.L, Wrozdek.C, Haring.H-U, Zell.A, Lehmann.R (2014) Integrated enrichment analysis and pathway-centered visualizationof metabolomics, proteomics, transcriptomics, and genomics data byusing the InCroMAP software. Journal of Chromatography B 966:77-82
  • Unterberger.E.B, Eichner.J, Wrzodek.C, Lempiainen.H, Luisier.R, Terranova.R,
    Metzger.U, Plummer.S, Knorpp.T, Braeuning.A, Moggs.J, Templin.M.F, Honndorf.V, Piotto.M, Zell.A and Schwarz.M (2014) Ha-ras and b-catenin oncoproteins orchestrate metabolic programs in mouse liver tumors. International Journal of Cancer Research 135(7):1574-85
  • Luisier.R, Lempiainen.H, Scerbichler.N, Braeuning.A, Geissler.M, Dubost.V, Muller.A, Scheer.N, Chibout.S-D, Hara.H, Picard.F, Theil.D, Coutter.P, Vitobello.A, Grenet.O, Grasl-Kraupp.B, Ellinger-Ziegelbauer.H, Thomson.J.P, Meehan.R.R, Elcombe.C.R, Henderson.C.J, Wolf.C.R, Schwarz.M, Moulin.P, Terranova.R, Moggs.J.G (2014) Phenobarbital Induces Cell Cycle Transcriptional Responses in Mouse Liver Humanized for Constitutive Androstane and Pregnane X Receptor. Toxicological Sciences 139(2):501-511
  • Luisier.R, Unterberger.E.B, Goodman.J.I, Schwarz.M, Moggs.J, Terranova.R, van Nimwegen.E (2014) Computational modeling identifies key gene regulatory interactions underlying phenobarbital-mediated tumor promotion. Nucleic Acid Research,1-16
  • Laird.A, Thomson.J.P, Harrison.D.J, Meehan.R.R. (2013) 5-hydroxymethylcytosine profiling as an indicator of cellular state. Epigenomics.5(6):655-69.
  • Klepeisz.P, Sagmeister.S, Haudek-Prinz.V, Pichbauer.M, Grasl-Kraupp.B, Gerner.C (2013) Phenobarbital Induces Alterations in the Proteome of
    Hepatocytes and Mesenchymal Cells of Rat Livers
    . PLoS ONE 8(10): e76137
  • Thomson.J.P, Hunter.J.M, Nestor.C.E, Dunican.D.S, Terranova.R, Moggs.J.G, Meehan.R.R (2013) Comparative analysis of affinity-based 5-hydroxymethylation enrichment techniques. Nucleic Acid Research , 1-15
  • Eichner.J, Kossler.N, Wrzodek.C, Kalkuhl.A, Bach Toft.D, Ostenfeldt.N, Richard.V, Zell.A. (2013) A toxicogenomic approach for the prediction of murine hepatocarcinogenesis using ensemble feature selection. PLoS ONE 8(9): e73938.
  • Thomson.J.P, Hunter.J.M, Meehan.R.R. (2013) Deep C diving:mapping the low-abundance modifications of the DNA demethylation pathway. Genome Biology, 14:118
  • Rose.C.M, van den Driesche.S, Meehan.R.R, Drake.A.J. (2013) Epigenetic reprogramming: preparing the epigenome for the next generation. Biochem Soc Trans. 41 (3):809-14
  • Thomson.J.P, Moggs.J.G, Wolf.C.R, Meehan.R.R. (2013) Epigenetic profiles as defined signatures of xenobiotic exposure. Mutat Res. pii: S1383-5718(13)00231-3.
  • Reddington.J.P, Pennings.S, Meehan.R.R (2013) Non-canonical functions of the DNA methylome in gene regulation. Biochem.J 451, 13-25
  • Thomson J.P, Hunter J.M, Lempiainen H, Muller A, Terranova R, Moggs J.G, Meehan R.R (2013) Dynamic changes in 5-hydroxymethylation signatures underpin early and late events in drug exposed liver. Nucleic Acid Research, 1-16
  • Wrzodek C, Eichner J, Buchel F, Zell A (2013) InCroMAP: Integrated analysis of cross-platform MicroArray and Pathway data. Bioinformatics, 29 (4): 506-508
  • Lempiainen.H, Couttet.P, Bolognani.F, Muller.A et al. (2013) Identification of Dlk1-Dio3 imprinted gene cluster non-coding RNAs as novel candidate biomarkers for liver tumor promotion. Toxicological Sciences 131(2):375-386 .
  • Wrodek.C, Eichner.J, Zell.A. (2012) Pathway-based visualisation of cross-platform microarray datasets. Bioinformatics. 28(23):3021-6.
  • Thomson.J.P, Lempiainen.H, Hackett.J.A, Nestor.C.E, Muller. A, Bolognani.F, Oakley.E.J, Schubeler.D, Terranova.R, Reinhardt.D, Moggs.J.G, Meehan.R.R. (2012) Non-genotoxic carcinogen exposure induces defined changes in the 5-hydroxymethylome. Genome Biology 13 (10) :R93
  • Schmid A, Schmitz J, Mannheim J.G, Maier F.C, Fuchs K, Wehrl H.F, Pichler B.J (2012) Feasibility of Sequential PET/MRI Using a State of- the-Art Small Animal PET and a 1 T Benchtop MRI. Molecular Imaging and Biology
  • Wrzodek C, Buchel F, Hinselmann G, Eichner J, Mittag F, et al. (2012) Linking the Epigenome to the Genome: Correlation of Different Features to DNA Methylation of CpG Islands. PLoS ONE 7(4): e35327.
  • Schmid A, Rignall B, Pichler BJ, Schwarz M (2012) Quantative Analysis of the Growth Kinetics of Chemically-Induced Mouse Liver Tumors by Magnetic Resonance Imaging. Toxicological Sciences. 126 (1): 52-59
  • Lempiainen H, Muller A, Brasa S, Teo S-S, Roloff T.C et al (2011) Phenobarbital Mediates an Epigenetic Switch at the Constituative Androstane Receptor (CAR) Target Gene Cyp2b10 in the Liver of B6C3F1 Mice. PLoS ONE 6 (3): e18216.

Book Chapters

 

  • Lempiainen.H, et al (2012) Epigenomics for Drug Safety Sciences. In Sahu. S.C (Ed), Toxicology and Epigenetics (pp365-386), John Wiley and Sons Ltd.

Conference Presentations

 

  • Heidrun Ellinger-Ziegelbauer - Early microRNA and other non-coding RNA biomarkers for rodent non-genotoxic carcinogens. 50th Congress of the European societies of Toxicology. Edinburgh, UK, 8th September 2014
  • Eva Zeller - Gtl2/Meg3 - a marker for hepatocarcinogenesis? 2nd meeting of Pharmacology and Toxicology in Baden-Wurttemberg, Heidelberg, Germany, 25th July 2014
  • Richard Meehan - Dynamic changes in 5-hydroxymethylation (5hmc) signatures underpin late events in drug exposed liver. Clinical Epigenetics, Part of the Fifth International Clinical Genomics & Informatics Europe event. Lisbon, Portugal. 3rd December 2013.
  • Jonathan Moggs - Epigenomics - Impact for Drug Safety Sciences. HESI Application of Genomics to Mechanism-Based Risk Assessment Technical Committee Fall Symposium on: Advances in Assessing Adverse Epigenetic Effects of Drugs and Chemicals, Washington DC, 18th November 2013.
  • Richard Meehan - Advances in methods for assessing epigenomic modifications. HESI Application of Genomics to Mechanism-Based Risk Assessment Technical Committee Fall Symposium on: Advances in Assessing Adverse Epigenetic Effects of Drugs and Chemicals, Washington DC, 18th November 2013.
  • Roland Wolf - Defining Functions and Electron Transfer Pathways of the P-450 System in vivo, 18th International Conference on cytochrome P450, Seattle, Washington, 19th June 2013.
  • Richard Meehan - The Epigenetics of Identity - The Biochemical Society Event 'The new Epigenetic Mark: 5-Hydroxymethylcytosine - What is it's function', CRUK, Cambridge Institute, UK, 13th June 2013
  • Jonathan Moggs - Mechanistic insight and biomarker discovery via integrated epigenomic and transcriptomic profiling - ILSI Health and Environmental Sciences Institute, Human Cancer Risk Assessment Workshop, Paris, France, 17th May 2013
  • Marzieh Nejabat - Development of Mechnism Based Markers to Predict Non-Genotoxic Hepatocarcinogens in Early Drug Development - Austrian Society of Toxicology Symposium, Vienna, Austria, 21 March 2013
  • Teresa Reigler -The Mesenchymal - Parenchymal Interactions are Critical for Tumor Promotion by Phenobarbital - Austrian Society of Toxicology Symposium, Vienna, Austria, 21 March 2013
  • Florian Kellner - Adaptive Responses of Preneoplastic Hepatoctyes: Essential for Tumor Promotion by Non-Genotoxic Hepatocarcinogens? - Austrian Society of Toxicology Symposium, Vienna, Austria, 21 March 2013
  • Eva Zeller - Long non-coding RNA Gtl2/Meg3 and its role in hepatic cancer - 17th International AEK Cancer Congress, Heidelberg, Germany, 20th March 2013
  • Eva Zeller - Long non-coding RNA Gtl2/Meg3 and its role in hepatic cancer - 79th annual meeting of the Association of DGPT, Halle/Saale, Germany, 6th March 2013
  • Markus Templin - Protein Microarray Technologies - Analysis of Signaling Networks in Human Tumours - Key note presentation, Advances in Microarray Technology, Barcelona, Spain, 5th March 2013
  • Jonathan Moggs - Epigenetic Mechanisms and biomarkers for non-genotoxic carcinogenesis - Swiss Society of Toxicology Meeting, Basel, Switzerland, 22nd November 2012
  • John Thomson - The Potential of Chemicals to Cause Epigenetic Alterations - European Environmental Mutagen Society Conference, Warsaw, Poland, 16th September 2012
  •  

  • Roland Wolf - Application of Transgenic Animal Models to Predict Human Responses to Drugs and Chemical Toxins - Gordon Research Conference, Holderness, New Hampshire, 11th July 2012
  •  

  • Lynsey Chatham - Induction of oxidative stress by non-genotoxic carcinogens in a haem oxygenase 1 reporter mouse model - 7th International Meeting on Heme Oxygenases and Related Enzymes, Edinburgh, UK, 28th May 2012
  •  

  • Raphaelle Luisier - Prediction of early regulatory networks underlying liver non-genotoxic carcinogenesis upon xenobiotic exposure - Integrative Network Biology 2012: Network Medicine, Copenhagen, Denmark, 12th May 2012
  •  

  • Andreas Schmid - Feasibility of sequential PET and 1T bench-top-MRI studies - Nuclear Medicine 2012, Bremen, Germany, 26th April 2012
  •  

  • Federico Bologani - Comprehensive mapping of transcriptional and epigenetic perturbations in vivo identifies noncoding RNAs as novel biomarkers for liver tumor promotion - SOT 2012, San Francisco, California, 11th March 2012
  •  

  • Jonathan Moggs - Epigenomics - Impact for Drug Safety Science - SOT 2012, San Francisco, California, 11 March 2012
  •  

  • Harri Lempiainen - Epigenomics - Impact for Drug Safety Science - IMI SafeSciMet Course 4.5 Mutagenesis/Carcinogenesis, Vienna, Austria 30th November 2011
  •  

  • Simon Plummer - Integrated miRNA Microarray analysis in the contect of nongenotoxic rodent hepatocarcinogenesis - 47th Congress of the European Society of Toxicology (EUROTOX 2011), Paris, France 30th August 2011
  •  

  • Jonathan Moggs - Integrating epigenomic and transcriptomic biomarkers in rodent models of non-genotoxic hepatocarcinogenesis - 47th Congress of the European Society of Toxicology (EUROTOX 2011), Paris, France 29th August 2011
  •  

  • Richard Meehan - The use of a transgenic reporter model to evaluate the potential of chemicals to cause an epigenetic alteration - 47th Congress of the European Society of Toxicology (EUROTOX 2011), Paris, France 29th August 2011
  •  

  • Harri Lempiainen - Investigating Epigenetic Mechanisms of Drug-Induced Non-Genotoxic Carcinogenesis (NGC) - Epigenomics of Common Diseases conference, Cambridge UK 13th August 2011
  •  

  • Colin Henderson - Transgenic models in toxicology - Scottish Toxicology Interest Group, Aberdeen, UK 15th June 2011
  •  

  • Colin Henderson - The application of transgenic models to study mechanisms of drug and chemical toxicity - ADMET 2011, Munich, Germany 28th March 2011
  •  

  • Jonathan Moggs - Epigenetic mechanisms and biomarkers of non-genotoxic carcinogenesis - British Toxicology Society & The Dutch Society of Toxicology - Joint Congress, Durham, UK 27th March 2011
  •  

  • Jonathan Moggs - One way the liver changes itself - demethylation epigenetics - FDA/CDER Drug Induced Liver Injury Workshop, Washington D.C. 24th March 2011
  •  

  • Jonathan Moggs - Epigenomics - Impact for Translational Sciences - 6th Annual Biomarkers Congress & 1st Oncology Biomarkers Congress, Manchester, UK 21st February 2011
  •  

  • Remi Terranova - Investigating Epigenetic Mechanisms of Drug-Induced Non-Genotoxic Carcinogenesis - Gordon Conference: Genetics and Epigenetics of Cancer, Ventura, CA 17th January 2011
  •  

  • Stephane Dhalluin - MARCAR, A new innovative medicines initiative project focusing on non-genotoxic carcinogenesis Insights into the Innovative Medicines Initiative MARCAR project (2010-2014) BioMARkers& molecular tumorclassification for non-genotoxicCARcinogenesis -  Preclinical Safety and Efficacy testing of biological products, Berlin, Germany 1-2 December 2010
  •  

  • Harri Leimpanien - Epigenomics, Impact for Drug Safety Sciences - UK Advanced Toxicology Course on Epigenetics, Harrogate, UK 16th & 17th November 2010
  •  

  • Stephane Dhalluin - Insights into the Innovative Medicines Initiative MARCAR project (2010-2014) BioMARkers& molecular tumorclassification for non-genotoxicCARcinogenesis - Carcinogenicity and genotoxicity conference, London, UK 19-20 October 2010
  •  

  • Jonathan Moggs - Epigenomics, Impact for Drug Safety Sciences -Hamner Institutes (US Centre for Drug Safety Sciences) NC, USA, 11th October 2010
  •  

  • Jonathan Moggs - Epigenomics, Impact for Drug Safety Sciences - Toxicogenomics & Xenobiotic/Drug Safety at ISSX 9th International Meeting, Istanbul, Turkey, 4th - 8th September 2010
  •  

  • Tom Shepherd - Liver mRNA & miRNA Profilling of Phenobarbital Treated PXR/CAR Double Knock-out & Humanised Mice Provides Insights into Mechanism(s) of PB-Mediated Mouse Hepatocarciongenesis - Society of Toxicology, 49th Annual Meeting and ToxExpo, Salt Lake City, Utah, USA  8-11 March 2010
  •  

  • Jonathan Moggs - Epigenomics, Impact for Drug Safety Sciences - 5th Annual International Conference on Predictive Human Toxicity and ADME/Tox Studies. Brussels, Belgium, 28th - 29th January 2010

General Information

 

  • 4th December 2014 - MARCAR Coordinator Dr Jonathan Moggs participated in the IMI-FDA-EMA summit on the impact of collaborative research on advancing regulatory science in Washington, USA.
  • 13th November 2014 - MARCAR Coordinator Dr Jonathan Moggs gave a presentation on MARCAR at the Swiss Society of Toxicology Annual Meeting, Basel
  • 15th August 2013 -MARCAR Partner Richard Meehan (University of Edinburgh) has released a video describing work on a new epigenetic modification: 5-hydroxymethylcytosine (watch here)
  • 9th October 2012 - MARCAR Coordinator Dr Jonathan Moggs gave a presentation on New developments and opportunities for enhancing preclinical carcinogenicity testing strategies at the BioSafe Annual Leadership Meeting.
  • 5th October 2011 - MARCAR Coodinator Dr Jonathan Moggs gave a presentation at the EFPIA Meeting with EMA and FDA titled "MARCAR consortium focus on novel mechanisms& biomarkers for non-genotoxic carcinogenesis"
  • 14th June 2010 - MARCAR Coordinator Dr Jonathan Moggs gave a presentation on the MARCAR project to the IMI JU Stakeholder Meeting - view presentation